TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00480532
Drug: Subantimicrobial doxycycline daily
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
Study: NCT00480532
Drug: placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for the first 84 days of the study
Study: NCT03524157
Drug: PRO-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Study: NCT03524157
Drug: Xyel Ofteno
Normalized name: Nazil Ofteno 0.02 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Study: NCT00784017
Drug: recombinant asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
Study: NCT00659022
Drug: neoadjuvant treatment with capecitabine and oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
Study: NCT00710619
Drug: Feiba VH
Normalized name: Feiba VH Immuno
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
Study: NCT00011635
Drug: Silymarin (milk thistle)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01514357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
Study: NCT03421353
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement.
Study: NCT03421353
Drug: 5-Flourouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
Study: NCT02886962
Drug: Oral anticoagulation with vitamin K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week
Study: NCT01208766
Drug: 1 or 2 cycle(s) HDM (High Dose Melphalan)
Normalized name: Inova 8-2 Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.
Study: NCT04318938
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with any TKI
Study: NCT04501120
Drug: standard-dose HHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
Study: NCT00413712
Drug: Calcium Channel Blocker & Adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04391569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT00829868
Drug: SONATA® 10 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT01446523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup, 30 ml BD for 3 months in Gr. NL
Study: NCT01241500
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
Study: NCT00061711
Drug: Multibotanical phytoestrogen formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362790
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
Study: NCT02038647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching tablets
Study: NCT04728425
Drug: subcutaneous immunoglobulin (SCIG)
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% subcutaneous immunoglobulin
Study: NCT04728425
Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
Study: NCT00044785
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00044785
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03598348
Drug: Apatinib+Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
Study: NCT02444260
Drug: Bupivocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
Study: NCT00725855
Drug: Placebo for MEM 3454
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose
Study: NCT00386581
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03935347
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02304185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
Study: NCT01408030
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9%, 0.1 ml spray in each nostril bid
Study: NCT04233892
Drug: Collagen/BMMNCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
Study: NCT00938574
Drug: Atu027
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00925574
Drug: CNTO 1959; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01408030
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
Study: NCT03524066
Drug: Inhalation
Normalized name: INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
Study: NCT03524066
Drug: Systemic
Normalized name: Fluorouracil, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
Study: NCT01096121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose
Study: NCT03437720
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Study: NCT03437720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Study: NCT02280850
Drug: Guanxin Shutong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02280850
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules three times a day; Duration: 4 weeks.
Study: NCT02496000
Drug: ORMD-0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Insulin
Study: NCT02496000
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01111552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug matching placebo capsule.
Study: NCT02796911
Drug: Xenograft
Normalized name: Xenograft heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
Study: NCT02796911
Drug: Bioactive glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
Study: NCT00309842
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
Study: NCT05399212
Drug: FPT-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
Study: NCT02371187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Study: NCT03268278
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1,8 ml
Study: NCT03268278
Drug: lidocaine, epinephrine (Local anesthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 1:100,000 epinephrine
Study: NCT04070846
Drug: [14C] LC350189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon-14 labelded LC350189
Study: NCT03499743
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
Study: NCT03499743
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
Study: NCT01516476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks
Study: NCT01516476
Drug: RO6807952
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses for 12 weeks
Study: NCT01175746
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1-0.5 ugkg/min during hypotensive anesthesia
Study: NCT04003402
Drug: ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04003402
Drug: ASP8062 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04003402
Drug: Alcohol Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04028167
Drug: Sequential FLOT followed by chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
Study: NCT02586194
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03168984
Drug: UCB0942
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use
Study: NCT03148002
Drug: PEG Bowel Protocol (PEG/lactulose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic Laxatives.
Study: NCT02048007
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Biannual mass oral azithromycin to children
Study: NCT02048007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass oral placebo to children
Study: NCT00999557
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically
Study: NCT00863304
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 1000 mg daily for 16 weeks
Study: NCT03921567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
Study: NCT04687930
Drug: intra-articular steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinilone injection into the knee joint under ultrasound guidance.
Study: NCT03079999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily placebo
Study: NCT03685149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study: NCT01370044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 minutes administration of oxygen
Study: NCT03864328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo administered TID via eFlow nebulizer
Study: NCT03941561
Drug: S-1 for 9 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 for 9 months after D2 resection
Study: NCT03941561
Drug: S-1 for 1 year
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 for 1 year after D2 resection
Study: NCT00167245
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT02172157
Drug: BI 1744 CL i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01767987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
Study: NCT02835105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of placebo for surotomycin in hard gelatin capsules
Study: NCT04148209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo
Study: NCT02014376
Drug: SD-101 dermal cream (3%)
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
Study: NCT02014376
Drug: SD-101 Dermal Cream (6%)
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study: NCT00517790
Drug: ABT-869 .25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Study: NCT00517790
Drug: ABT-869 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Study: NCT01172392
Drug: Nucleotidic or Nucleosidic Treatment
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analog treatment according to investigators practice
Study: NCT01331655
Drug: EE20/DRSP (BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
Study: NCT01331655
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
Study: NCT01331655
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
Study: NCT00105066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet once a day for one month, then twice a day for 3 months
Study: NCT00159445
Drug: gemcitabine, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03321942
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
Study: NCT03321942
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment were used to treat patients with chronic renal failure.
Study: NCT00741377
Drug: BHQ880
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741377
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00706173
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 10-20 mg PO daily for 4 weeks.
Study: NCT00706173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10-20 mg PO daily for 4 weeks.
Study: NCT00619866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally
Study: NCT00240266
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02129621
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
Study: NCT00471393
Drug: 1.5% diclofenac in 45.5% DMSO (topical treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00471393
Drug: 45.5% DMSO (topical placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965274
Drug: Torrent's Fluoxetine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965274
Drug: Warner Chilcott LLC's Sarafem Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04102566
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
Study: NCT03070665
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
Study: NCT03436849
Drug: ESN364
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESN364 will be administered orally.
Study: NCT03436849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT00916747
Drug: Lonafarnib, Zoledronic Acid, and Pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.
Study: NCT01136850
Drug: azithromycin, sulphadoxine pyrimethamine, LLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.
Study: NCT01342315
Drug: 33525
Normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing
Study: NCT01342315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing
Study: NCT00075582
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00867152
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
Study: NCT01950520
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 200mg, oral, by mouth (Cohort 2 only)
Study: NCT01950520
Drug: Placebo Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, by mouth (Cohort 1 only)
Study: NCT01950520
Drug: Placebo Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, by mouth (Cohort 2 only)
Study: NCT03344705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days